Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-22
2006-08-22
Martinell, James (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07094767
ABSTRACT:
Genes encoding herpes simplex virus type 2 (HSV-2) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. In a DNA titration, it was found that a single immunization of ≧0.5 μg of (one) PNV, gave >90% seroconversion by ten weeks post immunization. Immune antisera neutralized both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p<0.001) protection from lethal infection was achieved following PNV vaccination. DNA constructs may be full-length, truncated and/or mutated forms and may be delivered along or in combination in order to optimize immunization and protection from HSV infection.
REFERENCES:
patent: 4374127 (1983-02-01), Larson et al.
patent: 5244792 (1993-09-01), Burke et al.
patent: 0 406 857 (1991-01-01), None
patent: WO 88/00971 (1988-02-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 9603510 (1996-02-01), None
Cox et al, J. Virol. 67(9): 5664 (1993).
Gallichan, W. et al. “Mucosal Immunity and Protection after Intranasal Immunization with Recombinant Adenovirus Expressing Herpes Simplex Virus Glycoprotein B”. The Journal of Infe. Disease 1993, vol. 168, pp. 622-629.
Byars et al. “Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficaious adjuvant formulation elicits protection against vaginal infection”; Vaccine 1994, vol. 12, No. 3, pp. 200-209.
Straus et al. “Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine”, J. of Infectious Diseases, vol. 167, pp. 1045-1052 (1993).
Ghiasi et al. “Expression of Seven Herpes Simplex Virus Type 1 Glycoproteins (gB, gC, gD, gE, gG, gH and gI): Comparative Protection against Lethal Challange in Mice”; J. Virology, Apr. 1994, pp. 2118-2126.
Wachsman et al. “Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes in glycopretein D”, Vaccine, vol. 10, No. 7, pp. 447-454. (1992).
Ghiasi et al. “Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D”, Arch. Virol (1991) 121: 163-178.
Burke, “Current developments in herpes simplex virus vaccines”, Virology, vol. 4, 1993, pp. 187-197.
Burke, “Development of a Herpes Simplex Virus Subunit Glycoprotein Vaccine for Prophylactic and Therapeutic Use”, Reviews of Infectious Diseases, vol. 13, Suppl 11, p S906-S911 (1991).
Lasky, “From Virus to Vaccine: Recombinant Mammalian Cell Lines as Substrares for the Production of Herpes Simplex Virus Vaccines”, J. of Med. Virology, 31:pp. 59-61 (1990).
Aurelian et al. “Immune Responses to Herpes Simplex Virus in Guinea Pigs (Footpad Model) and Mice Immunized with Vaccinia Virus Recombinants Containing Herpes Simplex Virus Glycoprotein D”, Review of Infec. Diseases, vol. 13, (Suppl 11) S924-934 (1991).
Rooney et al. “Live Vaccinia Virus Recombinants Expressing Herpes Simplex Virus Genes”, Reveiws of Infec. Diseases, vol. 13 (Suppl 11) p S898-903 (1991).
Ritchie et al. “Passive Transfer of Anti-Herpes Simplex Virus Type 2 Monoclonal and Polyclonal Antibodies Protect Against Herpes Simplex Virus Type 1-induced but not Herpes Simplex Virus Type 2-induced Stromal Keratitis”, Invest. Ophthal & Vis. Science, vol. 34, No. 8, pp. 2460-2468 (1993).
Montgomery et al. “Heterologous and Homologous Protection Against Influenza A by DNA vaccination: Optimization of DNA Vectors”, DNA and Cell Biology, vol. 12, No. 9, pp. 777-783 (1993).
Ulmer et al. “Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein”, Science, vol. 259, pp. 1745-1749 (1993).
Browne et al. “Analysis of protective immune responses to the glycoprotein H-glycoprotein L complex of herpes simplex virus type 1”, J. of Gen. Virology, Vo. 74, pp. 2813-2817 (1993).
Stanberry et al. “Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital Herpes”, Jour. of Infec. Dis., vol. 155, No. 5, pp. 914-920 (1987).
Eisenberg et al. “Synthetic Glycoprotein D-related Peptides Protect Mice against Herpes Simplex Virus Challange”, J. of Virology, vol. 56, No. 3, pp. 1014-1017 (1985).
Long et al. “Glycoprotein D Protects Mice Against Lethal Challange with Herpes Simplex Virus Types 1 and 2”, Infec. and Immunity, vol. 37, No. 2, pp. 761-764 (1984).
Dix et al. “Use of Monolonal Antibody Directed Against Herpes Simplex Virus Glycoprotein to Protect Mice Against Acute Virus-Induced Neurological Disease”, Infection and Immunity, vol. 34, No. 1, pp. 192-199 (1981).
Stanberry et al. “Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy”, Antiviral Res. vol. 11, pp. 203-214 (1989).
Kino et al. “Immunogenicity of herpes simplex virus glycoprotein gB-1 related protein produced in yeast”, Chemo-Sero-Ther. Res. Inst. Japan (1988).
McDermott et al. “Protection of Mice against Lethal Challange with Herpes Simplex Virus . . . Expressing HSV Glycoprotein B”, Virology, vol. 169, pp. 244-247 (1989).
Schmid et al. “The Role of T cell Immunity in Control of Herpes Simplex Virus”, Current Topics in Microbiology and Immunology, vol. 179, pp. 57-74 (1992).
Banks et al. “Recognition by and in Vitro Induction of Cytotoxic T Lymphocytes against Predicted Epitopes of the Immediate-Early Protein ICP27 of Herpes Simplex Virus”, J. of Virology, vol. 67, No. 1, pp. 613-616 (1993).
Watanabe et al. “Induction of Antibodies to a KV Region by Gene Immunization”, J. of Immuno. vol. 151, pp. 2871-2876 (1993).
Ellis et al. “New Vaccine Technologies”, JAMA, vol. 271, No. 12, pp. 929-931.
Ho et al. “Liposome formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea pigs”, Vaccine, vol. 10, Issue 4, pp. 209-213 (1992).
Friedman, “Progress Toward Human Gene Thereapy”, Science, vol. 259, pp. 1275-1281 (1989).
Edgington, “Turning on Tumor Fighting T-Cells”, Bio/Technology, vol. 11, Oct. 1993, pp. 1117-1119 (1993).
Manickan et al. “Protection against HSV infection by DNA vaccination: plasmid DNA encoding HSV-1 gB protects mice from HSV-1 zosteriform lesions”, FASEB Jour. vol. 9, No. 3 p. A207 and Exper. Biol. 95, Part 1, Atlanta GA, USA (Apr. 9-13) (1995).
Ghiasi et al. “Vaccination of mice with herpes simplex virus type 1 glycoprotein-D DNA produces low levels of protection against lethal HSV-1 challange”, Antiviral Res. vol. 28, No. 2, pp. 147-157 (1995).
Marwick, “Exciting Potential of DNA Vaccines Explored”, JAMA, vol. 273, No. 18, pp. 1403-1404 (1995).
Liu et al. “Immune responses and pre-clinical efficacy of DNA vaccines for viral diseases”, Int. Pharm. J., vol. 9, Suppl. 1, 10 (1995).
Shinya, “Recombinant DNA Integration with Herpes Simplex Gene . . . ”, Patent Abstract of Japan, vol. 11, 332 (1987).
McClements et al. Prevention of LEthal HSV-2 Infection in Mice by Immunization with DNA encoding HSV-2 Glycoproteins, 20th Ann. Herpesvirus Workshop, Abs. #359, 1995.
McClements et al. “Immunization with DNA Vaccines Encoding GlcD or GlcB, alone or in combination, induces . . . ”, Proc. Natl. Acad. Sci., vol. 93, pp. 11414-11420, (1996).
Lasky et al. “DNA Sequence Anlaysis of the Type-Common Glycoprotein-D Genes of Herpes Simplex Virus Types 1 and 2”. DNA, vol. 3, No. 1, pp. 23-29.
Armstrong Marcy E.
Keys Robert D.
Lewis John A.
Liu Margaret A.
McClements William L.
Martinell James
Merck & Co. , Inc.
LandOfFree
Polynucleotide herpes virus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotide herpes virus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide herpes virus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608668